Moderna (MRNA) PT Lowered to $201 at Morgan Stanley on Higher Costs
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison lowered the price target on Moderna (NASDAQ: MRNA) to $201.00 (from $215.00) after the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
